TRX vs. SFR, NAK, EGI, IMG, EDG, MTA, NGR, RRS, NG, and WPM
Should you be buying Tissue Regenix Group stock or one of its competitors? The main competitors of Tissue Regenix Group include Severfield (SFR), Nakama Group plc (NAK.L) (NAK), (EGI.L) (EGI), 532753 (IMG.L) (IMG), 651814 (EDG.L) (EDG), ArcelorMittal (MTA), Nature Group (NGR), Randgold Resources (RRS), National Grid (NG), and Wheaton Precious Metals (WPM). These companies are all part of the "precious metals" industry.
Tissue Regenix Group vs. Its Competitors
Tissue Regenix Group (LON:TRX) and Severfield (LON:SFR) are both small-cap precious metals companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.
37.0% of Tissue Regenix Group shares are held by institutional investors. Comparatively, 66.9% of Severfield shares are held by institutional investors. 47.3% of Tissue Regenix Group shares are held by insiders. Comparatively, 4.4% of Severfield shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Severfield has a net margin of 3.43% compared to Tissue Regenix Group's net margin of -3.46%. Severfield's return on equity of 7.24% beat Tissue Regenix Group's return on equity.
In the previous week, Severfield had 2 more articles in the media than Tissue Regenix Group. MarketBeat recorded 2 mentions for Severfield and 0 mentions for Tissue Regenix Group. Tissue Regenix Group's average media sentiment score of 0.00 beat Severfield's score of -0.04 indicating that Tissue Regenix Group is being referred to more favorably in the media.
Tissue Regenix Group has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500. Comparatively, Severfield has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.
Severfield has higher revenue and earnings than Tissue Regenix Group. Tissue Regenix Group is trading at a lower price-to-earnings ratio than Severfield, indicating that it is currently the more affordable of the two stocks.
Summary
Severfield beats Tissue Regenix Group on 9 of the 13 factors compared between the two stocks.
Get Tissue Regenix Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tissue Regenix Group Competitors List
Related Companies and Tools
This page (LON:TRX) was last updated on 8/7/2025 by MarketBeat.com Staff
Free TRX Stock Alerts